View this email in your browser Numinus

Psychedelic Finance Feature Currently private, Numinus is expected to list on the TSXV in late March under the ticker $NUMI and will be one of the first publicly traded companies licensed to test, sell and deliver psychedelic therapies.



Numinus Website

Numinus Investor Presentation

Most Recent Press Release

Numinus recently completed an over-subscribed private placement and is expected to announce an over-subscribed sub receipt financing shortly, positioning the company well for execution and growth opportunities. About:

Numinus is a fully integrated operating company at the forefront of the transformative change in treating the growing prevalence of mental health issues and desire for greater wellness.



They will be one of the first publicly traded companies licensed to test, sell and deliver psychedelic therapies.



Their unique growth platform includes a testing and processing facility that can leverage the emerging market of psychedelic therapies to treat mental illness, addictions and PTSD, as well as an established and fully integrated treatment and healing centre model that they plan to scale nationally.



Sustainable cannabis revenue through their laboratory and processing facility will help fund growth plans. Market: The growing number of those suffering from PTSD, addictions and mental health issues underserved by today’s therapeutic model.



Those who desire improved well-being by taking advantage of the wide range of therapeutic services offered at Numinus Healing Centres. Team:

Payton Nyquvest, Chief Executive Officer

- Former Director, VP, and Head of Sales at Mackie Research

- 15 years experience in investment banking, has raised over $100 million for 100+ companies



Stacey Wallin, Chief Strategy Officer

- Former Director of Venture Programs at the BC Tech Association

- Founder and CEO of LifeBooster Summary: Numinus is a growth story in the emerging psychedelic therapy space. With plans to expand their clinical footprint to 2-4 new locations and the first licensed testing facility for psychedelics, their model is able to support both individual patients and larger healthcare providers.